What the FDA’s New Companion Diagnostics Ruling Means – and Why DNAe Supports The Move
The U.S. Food and Drug Administration (FDA)’s recent proposal to reclassify a major group of oncology companion diagnostics from Class III (PMA) to Class II (510 (k)) marks one of the most significant regulatory shifts in precision medicine in more than a decade.
The proposed reclassification – Docket No. FDA-2025-N-4622 – reflects FDA’s evolving view that for certain nucleic acid-based oncology tests, including companion diagnostics, safety and effectiveness can be adequately assured through targeted special controls rather than PMA-level oversight.
For companies developing next‑generation sequencing (NGS) diagnostics – including DNAe – this change represents a meaningful step toward a more agile, innovation‑friendly regulatory environment, while maintaining the rigorous safety and effectiveness standards patients rely on.
A Structural Shift in CDx Oversight
Historically, most companion diagnostics (CDx) have been regulated as Class III devices, requiring Premarket Approval (PMA) – the FDA’s most stringent pathway for medical devices. The new proposal would move many nucleic‑acid‑based oncology CDx devices, including NGS panels, PCR assays, and mutation-specific tests, into Class II with special controls, under a new device classification regulation at 21 CFR 866.6075.
In short, the FDA now believes that many oncology CDx devices can be safely and effectively regulated through the 510(k) pathway, provided that they meet clearly defined special controls.
Importantly for DNAe, the proposed scope explicitly includes NGS-based test systems used as companion diagnostics with approved oncology therapeutics. This proposal reflects FDA’s recognition that oncology NGS technologies have matured, and that their risks are well understood and manageable through risk-based controls.
Why DNAe Supports the FDA’s Direction
As we see it, the proposed reclassification enables a regulatory framework that boosts innovation and better supports lifecycle management.
The proposal acknowledges more ‘modern’ validation and lifecycle management approaches. The FDA is signalling flexibility in how analytical performance may be demonstrated, and recognizes the role of structured, predetermined change control plans for managing post-market updates. This reflects an understanding that NGS-based diagnostics are dynamic systems that benefit from continuous improvement without compromising patient safety.
From our perspective, this proposed reclassification aligns closely with how we plan to design, validate, and manage our diagnostic platforms. We support FDA’s recognition that not all performance evaluations require extensive wet testing, and that computational, in silico, and other scientifically justified methods can play an appropriate role in demonstrating analytical performance.
Enabling innovation without compromising safety
DNAe believes that the proposed rule represents a meaningful step toward a more predictable, efficient and science-driven regulatory framework for oncology diagnostics – one that strikes the right balance between innovation and patient protection.
DNAe’s mission is to deliver rapid, accurate, sample‑to‑answer NGS diagnostics that transform how clinicians detect and manage disease. The FDA’s updated framework supports this mission by:
- Encouraging technological advancement
- Allowing more iterative development
- Reducing time to clinical impact
Looking Ahead
The FDA’s proposed reclassification is a welcome modernization of CDx oversight. It recognizes the maturity of molecular diagnostics, supports innovation in NGS technologies, and ensures that safety and effectiveness remain at the core of regulatory decision‑making.
For DNAe, this is an important step toward a future where rapid, integrated NGS diagnostics can reach patients and deliver clinical benefit faster – without compromising the scientific rigor that underpins trust in precision medicine.
